Skip to main content
main-content

01.12.2017 | Case report | Ausgabe 1/2017 Open Access

BMC Neurology 1/2017

Parasomnia overlap disorder, Parkinson’s disease and subthalamic deep brain stimulation: three case reports

Zeitschrift:
BMC Neurology > Ausgabe 1/2017
Autoren:
Panagiotis Bargiotas, Julia Muellner, W.M. Michael Schuepbach, Claudio L. Bassetti
Abbreviations
AHI
Apnea-hypopnea index
COMT
Catechol-O-Methyltransferase
DBS
Deep brain stimulation
DEB
Dream-enacting behavior
EEG
Electroencephalography
EMG
Electromyography
ESS
Epworth sleepiness scale
ICSD-III
The international classification of sleep disorders – third edition
LEDD
Levodopa equivalent daily dose
MAO
Monoaminooxidase
NREM
Non-rapid eye movement
PD
Parkinson’s disease
POD
Parasomnia overlap disorder
RBD
REM sleep behavior disorder
REM
Rapid eye movement
STN
Subthalamic nucleus
v-PSG
Video polysomnography

Background

Parasomnia overlap disorder (POD) is a distinct parasomnia and characterized by concomitant manifestation of rapid-eye-movement (REM)- and non-REM (NREM)-parasomnias. There are only limited data on the prevalence of POD in the course of Parkinson’s disease (PD), and a previous questionnaire-based study reported that 26 out of 417 (6%) PD patients reported sleepwalking and also features of REM behavior disorder (RBD), suggesting the presence of POD. [1] To the best of our knowledge, this is the first report of PD patients with POD features in the context of subthalamic deep brain stimulation (STN-DBS).

Methods

Standard video-polysomnography (v-PSG) was performed in all presented cases as previously described. [1] The v-PSG consisted of six channel EEG (F3/A2, F4/A1, C3/A2, C4/A1, O1/A2, O2/A1), left and right electrooculography, submental, left and right anterior tibialis, flexor carpi radialis and adductor digiti minimi electromyography, electrocardiography, respiratory flow and effort, and pulse-oximetry. All recordings were performed by Embla RemLogic™ Software. Sleep stages and sleep-associated events were manually scored according to the ICSD-III [2].
Levodopa equivalent daily dose (LEDD) was calculated as previously described (including all commonly used medications in PD patients such as dopamine agonists, MAO-B inhibitors, COMT-inhibitors etc.) [3].

Case presentations

Case 1

Patient 1, female, age 70 was diagnosed in 1999 with tremor-dominant PD, underwent bilateral STN-DBS in 2015. Since 2012, the quality of sleep gradually deteriorated mainly due to disrupted night sleep and early morning awakening resulting in daytime sleepiness (Epworth Sleepiness Scale, ESS:12/24). She reported weekly sleep-talking but no sleep-walking or dream-enacting behavior (DEB).
In v-PSG prior to STN-DBS, quantification of EMG-activity [4] showed increased phasic/tonic muscle activity and several episodes of DEB during REM-sleep. NREM-parasomnia included repeated mumbling, sleep-talking and confusional arousals.
STN-DBS was well received and 1 year after surgery, motor signs, assessed by Unified Parkinson’s Disease Rating Scale (UPDRS) part III, were ameliorated (57%) and LEDD was reduced by 91% (from 885 mg to 75 mg). Pregabaline 50 mg (prescribed due to very mild restless legs symptoms) and quetiapine 25 mg were gradually stopped after DBS surgery. The rest of medication (levothyroxine and painkillers) remained unchanged.
Sleep quality and daytime sleepiness (ESS 5/24) improved and sleep-talking became rare. Sleep architecture improved markedly (Fig. 1, a1–2). Awakenings from stage 3 NREM were present but showed no episodes of DEB or confusional arousals. Compared to baseline, EMG showed a 44% reduction in tonic and 8% reduction in phasic activity. Apnea–Hypopnea Index (AHI) improved from 19.2/h to 9.2/h.
At the time of postoperative assessments stimulation parameters were:
STN (right): monopolar stimulation, C + 9-, 60 msec pulse width, 2.5 V amplitude and 125 Hz repetition / STN (left): interleave stimulation, a) C + 1-, 2.2 V (2.0–3.4 V) amplitude, 60 msec pulse width, 125 Hz repetition and b) C + 0-, 60 msec pulse width, 2.5 V amplitude, 125 Hz repetition.

Case 2

Patient two, male, age 75, was diagnosed with rigid-hypokinetic PD in 2002, underwent bilateral STN-DBS in 2015. He reported refreshing sleep of good quality, no insomnia and only minor daytime sleepiness (ESS 7/24). His wife reported occasional episodes of sleep-walking, sleep-talking and DEB.
v-PSG prior to STN-DBS revealed increased phasic/tonic muscle activity [4] and several episodes of DEB during REM sleep as well as NREM-parasomnia including bruxismus, movements of all four extremities, sleep-talking, sounds of laughing/crying and grimacing several times throughout the night.
STN-DBS was well received and 1 year after surgery, motor signs, assessed by UPDRS part III, improved (50%) and LEDD was reduced by 70% (from 1500 mg to 460 mg). The rest of the medication (painkillers) remained unchanged. Sleepiness slightly improved (ESS 3/24), however, sleep quality deteriorated and his wife reported that frequency of sleepwalking and DEB doubled after DBS. In v-PSG, sleep architecture showed no significant changes (Fig. 1, b1–2). During REM sleep, while tonic activity was reduced (from 36 to 15% of total REM sleep), phasic activity increased (from 22 to 28%). During stage 3 NREM, episodes of confusional arousal were captured. AHI changed from 7/h to 2/h.
At the time of postoperative assessments stimulation parameters were:
STN (right): bipolar stimulation, 9–10+, 5.5 V (4.9–6.1 V) amplitude, 60 msec pulse width, 130 Hz repetition /STN (left): bipolar stimulation, 2–3+, 4.5 V (4.5–5.1 V) amplitude, 60 msec pulse width, 130 Hz repetition.

Case 3

Patient three, male, age 55, diagnosed with tremor-dominant PD in 1994, underwent bilateral STN-DBS in 2003. Prior to STN-DBS, LEDD was 900 mg and sleep quality was poor (no sleep scores available).
After STN-DBS, motor signs improved (85% in UPDRS part III), sleep-wake functions remained unchanged and he remained free from dopaminergic medication until 2010 (at that time stimulation parameters were: STN (right): monopolar stimulation, C + 1-, 2.5Volt, 60 msec pulse width, and 145 Hz repetition/STN (left): monopolar stimulation, C + 1-, 3.5 V, 60 msec pulse width, 145 Hz repetition). Since 2010, LEDD was gradually increased from 0 mg to 560 mg (2013) and to 635 mg (2016) while the dose of venlafaxine 150 mg daily remained unchanged between 2010 and 2015 (2015 increased to a 300 mg dose). No anticholinergic drugs were given.
Since 2012, sleep quality progressively deteriorated, daytime sleepiness worsened (in 2012 ESS 07/24, in 2016 ESS 12/24), DEB frequency increased (previously only rare episodes were reported) and he developed prominent insomnia. Nocturnal behavior was characterized by sudden movements, unintelligible sounds and falling out of bed associated with vivid dreams and sleep-walking (2×/week).
v-PSGs in 2012 and 2014 illustrated a progressive increment in phasic/tonic muscle activity during REM sleep. NREM-parasomnia in 2012 included axial myoclonus, mumbling, sleep-talking, chewing, and spitting. In 2016, v-PSG showed a status dissociatus with constant movements of all extremities, sleep-talking, laughing, grimacing and tongue-clicking throughout the whole night (Fig. 1, c1–2). DEB-episodes coincided with “saw tooth waves” in EEG and REM, without associated muscle atonia. AHI gradually increased from normal in 2012 to 10/h in 2014 and 19/h in 2016.
At the time of 2016 postoperative assessments, stimulation parameters were:
STN (right): monopolar stimulation, C + 1-, 2.6 V amplitude, 60 msec pulse width, and 140 Hz repetition/STN (left): monopolar stimulation, C + 2-, 3.0 V, 90 msec pulse width, 130 Hz repetition.

Discussion and Conclusions

DBS is a well-established treatment for motor symptoms in PD. Despite the impact of sleep disturbances on quality of life of patients with PD, [5] only few DBS studies included sleep and polysomnographic assessments prior to and after surgery (for review see Eugster et al. [6]). Considering sleep-wake functions as an integral part of the DBS outcome in PD patients, we report the first three PD patients with features of POD that underwent STN-DBS.
The pathological substrate of POD in PD remains unclear. Previous studies implicated neurodegeneration at the brainstem, possibly Lewy pathology, [7] involving the ascending control of state transition and the descending control of muscle tone. [8] At the neural level, gross motor phenomena during REM or NREM sleep may arise from a dissociated activity between serotonergic neurons that modulate tonic motor activity and those in the raphe nuclei regulating REM-NREM states, [9] implicating serotonergic system in the motor activity during REM and NREM sleep that characterizes POD. Changes in sleep quality and behavior after STN-DBS can be attributed to improved mobility or respiration and changes in medication. However, STN-related neuronal pathways may also directly be involved in sleep physiology mainly through reciprocal projections to structures involved in generation and modulation of sleep stages (including raphe nucleus, pedunculopontine nucleus and laterodorsal tegmentum), [1012] and to regions that regulate circadian rhythms, mainly the thalamus [13, 14].
In the presented cases, it is difficult to disentangle the impact of STN-DBS, medication and disease progression itself on POD outcome. In cases 1 and 2, the very different course regarding outcome of POD features after STN-DBS underlies the important role of DBS itself or even differences in the stimulation parameters (e.g. bipolar vs monopolar stimulation) since in both cases there was a prominent LEDD reduction (90% and 70% respectively) and a comparable improvement in motor signs. In case 3, the alterations in sleep behavior, including deterioration of sleep quality, progressive development of POD and status dissociatus were observed only several years after STN-DBS and 2 years after readmission of dopaminergic therapy, underlying the important role of disease progression and possibly of the medication.
We expect that the reporting of these first patients will open the discussion about the need for more detailed and broad-spectrum assessments regarding parasomnias in PD patients that undergo DBS, with the goal of including these assessments in future prospective studies. This, not only will advance pre-DBS selection procedures, it will contribute to the improvement of postoperative therapeutic practice and may give new insights into the neurobiology of motor and sleep-wake control.

Acknowledgements

Not available.

Funding

Not available.

Availability of data and materials

The datasets used and/or analyzed for the current report are available from the corresponding author on reasonable request.

Authors’ information

The scoring and the quantification of phasic and tonic muscle atonia were performed by a single scorer, blinded to subject and time of examination. Sleep staging and respiratory event scoring were made according to ICSD-III.

Ethics approval and consent to participate

The protocol for the retrospective analysis of the data was approved by the local ethics committee (Kantonale Ethikkommission Bern). All three participants of this case report gave their consent to participate, have seen and read the submitted material and have signed a written consent for the publication of this manuscript.

Consent for publication

Written informed consent was obtained from all three patients for publication of this Case Report and any accompanying data. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

Panagiotis Bargiotas has received congress fees and travel reimbursements from Lundbeck Foundation. Julia Muellner has received travel grants from Ipsen Pharma and from COST Action. Michael Schuepbach reports receiving consulting fees from Medtronic and Aleva, and lecture honoraria from Zambon, Merz Pharma, as well as grant support from Boston Scientific, Ipsen, Actelion. Furthermore, he received congress fees and travel reimbursements from Boston Scientific and Zambon. Claudio Bassetti has received honoraria for consultancy, lectures, and board memberships from the following institutions/companies: Jazz, Servier, UCB, Zambon, Cephalon Lundbeck, Pfizer Bohringer Ingelheim. His research is currently supported by grants of the following institutions/companies: Swiss National Science Foundation (SNF), ResMed, Respironics, Vifor Pharma, UCB Pharma, Schweizerische Herzstiftung, Tropos Stiftung, Parkinson Schweiz.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Neurology 1/2017 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Meistgelesene Bücher in der Neurologie & Psychiatrie

  • 2016 | Buch

    Neurologie

    Das Lehrbuch vermittelt Ihnen das gesamte Neurologie-Prüfungswissen für Ihr Medizinstudium und bereitet auch junge Assistenzärzte durch detailliertes Fachwissen optimal auf die Praxis vor. Die komplett überarbeitete Auflage enthält sechs neue, interdisziplinäre Kapitel.

    Herausgeber:
    Werner Hacke
  • 2016 | Buch

    Komplikationen in der Neurologie

    Das Buch schildert Ereignisse im Rahmen der Neuromedizin, die während der Diagnostik und Therapie neurologischer Erkrankungen und Symptome auftreten können. Die Fallbeispiele sensibilisieren Sie für mögliche Risikofaktoren, um das Auftreten solcher Komplikationen zu vermeiden.

    Herausgeber:
    Frank Block
  • 2017 | Buch

    Facharztwissen Psychiatrie, Psychosomatik und Psychotherapie

    Leitsymptome, Untersuchungsmethoden, Krankheitsbilder, Notfälle & Co. – mit der Neuauflage des "Facharztwissens" sind Sie auf die Facharztprüfung in Psychiatrie und Psychotherapie optimal vorbereitet. In dieser 2. Auflage sind die Kapitel zu psychosomatischen Störungen deutlich ausgebaut.

    Herausgeber:
    Prof. Dr. Dr. Frank Schneider
  • 2019 | Buch

    Kompendium der Psychotherapie

    Für Ärzte und Psychologen

    Dieses Werk wendet sich an Ärzte und Psychologen, die an psychiatrischen und psychosomatischen Kliniken oder an Psychotherapeutischen Ausbildungsinstituten arbeiten und in den vorhandenen Lehrbüchern der Psychotherapie den Brückenschlag zur …

    Herausgeber:
    Tilo Kircher